BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV
February 15, 2017 at 18:25 PM EST
* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents